ClinicalTrials.gg
CompletedNCT07310563Updated Oct 13, 2026

A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity

A Phase 1 interventional study of AMG 133 and Ondansetron in Overweight and Obesity, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Dec 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
24th of 28
59 · median 275
Started
2024
with 4 others
Phase 1
14 of 28
3 open now
Registered
14th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 24th largest by enrollment, is one of 5 that started in 2024, is one of 14 in phase 1, and was the 14th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered alone and in combination with an antiemetic medication, ondansetron, in participants living with overweight or obesity.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

Keywords

  • Antiemetic
  • Drug-drug Interaction
  • AMG 133
  • Ondansetron
  • Overweight
  • Obesity
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 59 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants, between 18 and 65 years of age.
  2. > 25 kg/m\^2.

Exclusion criteria

Exclusion Criteria

  1. History or evidence of disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator, would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
  2. History of or active diabetes or > 6.5%.
  3. History or evidence of endocrine disorder.
  4. History of acute or chronic pancreatitis within 1 year, or elevation in serum lipase/amylase (> 2 x [ULN]), or fasting serum triglyceride level of > 500 mg/dL.
  5. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  6. Uncontrolled thyroid disease.
  7. History or current signs or symptoms of cardiovascular disease.
  8. A corrected for heart rate based on the Fridericia's method (QTcF) interval > 450 msec in male participants or > 470 msec in female participants or history/evidence of long QT syndrome.
  9. History of , intolerance, or allergy to AMG 133 or its ingredients.
  10. Any to ondansetron ODT according to the applicable labelling.
  11. or aspartate aminotransferase > 2 x the ULN.
  12. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before check-in.
  13. Current use or prior use of any glucagon-like peptide 1 receptor (GLP-1R) agonist, or glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist or antagonist within the past 3 months.
  14. Participant has received a dose of an medicinal product (IMP) within the past 30 days or 5 half-lives.
  15. Have previously completed or withdrawn from this trial or any other trial investigating AMG 133 or have previously received the IMP.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Low Dose AMG 133 without Ondansetron

    Participants will receive a single subcutaneous (SC) low dose of 70 mg AMG 133.

    Drug: AMG 133

  • Experimental
    High Dose AMG 133 without Ondansetron

    Participants will receive a single SC high dose of 350 mg AMG 133.

    Drug: AMG 133

  • Experimental
    Low Dose AMG 133 with Ondansetron

    Participants will receive a single SC low dose of 70 mg AMG 133 and ondansetron 8 mg orally disintegrating tablet (ODT) every 8 hours for 72 hours.

    Drug: AMG 133 · Drug: Ondansetron

  • Experimental
    High Dose AMG 133 with Ondansetron

    Participants will receive a single SC high dose of 350 mg AMG 133 and ondansetron 8mg ODT every 8 hours for 72 hours.

    Drug: AMG 133 · Drug: Ondansetron

Interventions

  • AMG 133 will be administered SC.

  • Ondansetron will be administered via ODT.

07

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of AMG 133

    Time frame: Up to Day 120

  2. Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133

    Time frame: Up to Day 120

  3. AUC from Time Zero to Infinity (AUCinf) of AMG 133

    Time frame: Up to Day 120

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Day 120

  2. Number of Participants with Serious AEs (SAEs)

    Time frame: Up to Day 120

  3. Number of Participants with Anti-AMG 133 Antibodies

    Time frame: Up to Day 120

08

Study locations

1 site
  • CenExel Collaborative Neuroscience Research, LLC Los Alamitos
    Los Alamitos, California 90720, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in May 2025, 4 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Dec 10, 2024
Primary completionActual
May 9, 2025
CompletionActual
May 9, 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07310563
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 10, 2024
Primary completion
May 9, 2025
Completion
May 9, 2025
Last update
Oct 13, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion